MedPath
HSA Approval

IPOLIPID CAPSULE 300 mg

SIN04902P

IPOLIPID CAPSULE 300 mg

IPOLIPID CAPSULE 300 mg

July 4, 1990

MEDOCHEMIE SINGAPORE PTE. LTD.

MEDOCHEMIE SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantMEDOCHEMIE SINGAPORE PTE. LTD.
Licence HolderMEDOCHEMIE SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

CAPSULE

ORAL

Medical Information

C10AB04

gemfibrozil

Manufacturer Information

MEDOCHEMIE SINGAPORE PTE. LTD.

MEDOCHEMIE LTD - Factory AZ

Active Ingredients

GEMFIBROZIL

300 mg

Gemfibrozil

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

IPOLIPID CAPSULE 300 mg - HSA Approval | MedPath